USFDA issues warning letter to Intas Pharma for lapses at its Gujarat plant

It said that the company "failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, etc."
Image used for representational purposes. (File Photo)
Image used for representational purposes. (File Photo)

NEW DELHI: The US Food and Drug Administration (USFDA) has pulled up Gujarat-based Intas Pharmaceuticals for manufacturing lapses, including failure of its quality control unit to ensure CGMP compliance.

In a warning letter, dated July 28, the US health regulator pointed out various manufacturing lapses at its Sanand-based manufacturing plant in Ahmedabad.

"This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals," the USFDA said.

"Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated..," it said.

The USFDA inspected the manufacturing facility from November 22 to December 2 last year. The USFDA has now sought a detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment among other things.

A warning letter is issued when the USFDA finds that a manufacturer has significantly violated its regulations.

It said that the company "failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity."

"You failed to ensure reliability of data relating to the quality of medicines produced at your facility. Our inspection revealed serious deviations, including but not limited to, inadequate oversight of original CGMP documents, deficient controls over computerised systems, insufficient laboratory investigations, and aborted chromatographic sequences," it said.

Senior facility managers failed to exercise their authority and responsibility to ensure reliable data, leading to severe data integrity deficiencies in production and laboratory departments, it added.

"Our investigators observed plastic bags filled with torn and discarded original CGMP documents in your quality control (QC) scrap area under a stairwell, in your general parenteral scrap room, and on a truck outside your facility," USFDA further said.

It also pointed out the company's failure to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards.

"Your firm failed to establish and follow required laboratory control mechanisms...Our inspection team identified examples of your analysts entering manual integration events that yielded passing results without adequate procedural controls or justification," it noted.

In previous inspections, including those which took place between May 20-28, 2019, similar CGMP observations were cited at the plant, it pointed out.

"Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations," it said.

Failure to address violations may also result in the FDA continuing to refuse admission of articles manufactured at the facility into the US market, the USFDA noted.

"After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence," it said.

The letter also makes clear that the company must correct the problem and provides directions and a timeframe for its plans for correction. FDA then checks to ensure that the company's corrections are adequate.

Related Stories

No stories found.

The New Indian Express